FindTrial
Sign In

CHANGES IN GLOMERULAR HEMODINAMICS PARAMETERS IN HIPERTENSIVE PATIENTS AFTER TREATMENT WITH LERCANIDIPINE

CHANGES IN GLOMERULAR HEMODINAMICS PARAMETERS IN HIPERTENSIVE PATIENTS AFTER TREATMENT WITH LERCANIDIPINE

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002232-26-ES
Enrollment
Unknown
Registered
2005-04-26
Start date
2004-11-04
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HYPERTENSION

Interventions

Trade Name: ZANIDIP Product Name: LERCANIDIPINE Pharmaceutical Form: Tablet Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 10- Trade Name: ZANIDIP Product

Sponsors

HOSPITAL 12 OCTUBRE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: PATIENTS WITH 18 YEARS OLD OR MORE, WITH ESSENCIAL HYPERTENSION, WITHOUT PREVIOUS FARMACOLOGIC TREATMENT Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: SECUNDARY OR SEVERY HYPERTENSION, CRONIC RENAL FAILURE, VASCULAR ILLNESS, TOXIC HABIT

Design outcomes

Primary

MeasureTime frame
Main Objective: TO ASSESS THE CHANGES IN GLOMERULAR FILTRATION PARAMETERS IN PATIENTS WITH HYPERTENSION AFTER 1 AND 12 WEEKS OF TREATMENT WITH LERCANIDIPINE 10-20 MG/DAY;Secondary Objective: TO ASSESS THE CHANGES IN THE RESISTANCE OF CORONARY ARTERY AND THE QUOTIENT AND TO DETERMINATE THE CHANGES IN THE ALBUMIN URINAL EXCRETION;Primary end point(s): CHANGES IN GLOMERULAR FILTRATION PARAMETERS AND THE GLOMERULAR PRESSION—

Countries

Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026